 Ethinylestradiol | |
 Drospirenone | |
| Combination of | |
|---|---|
| Ethinylestradiol | Estrogen |
| Drospirenone | Progestogen; Progestin; Antimineralocorticoid; Antiandrogen |
| Clinical data | |
| Trade names | With 30 μg ethinylestradiol: Yasmin, others With 20 μg ethinylestradiol: Yaz, Yasminelle, others |
| Other names | EE/DRSP |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a601050 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Estrogen; Progestin; Progestogen; Antimineralocorticoid; Antiandrogen |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Ethinylestradiol/drospirenone (EE/DRSP), sold under the brand name Yasmin among others, is a combination of ethinylestradiol (EE), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used as a birth control pill to prevent pregnancy in women.[2][3][4][5][6] It is also indicated for the treatment of moderate acne, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and dysmenorrhea (painful menstruation) in women.[3] The medication is taken by mouth and contains 30 μg EE and 3 mg DRSP per tablet (brand names Yasmin, others) or 20 μg EE and 3 mg DRSP per tablet (brand names Yaz, Yasminelle, Nikki, others).[4][5] A formulation with levomefolic acid (vitamin B9) has also been marketed (brand names Beyaz, Safyral, others), with similar indications.[7][8] EE/DRSP is marketed widely throughout the world.[9]
In 2020, it was the 145th most commonly prescribed medication in the United States, with more than 4 million prescriptions.[10][11]
See also
References
- ↑ "Drospirenone / estradiol (Angeliq) Use During Pregnancy". Drugs.com. 6 September 2018. Retrieved 18 March 2020.
- ↑ "Ethinylestradiol/Drospirenone". AdisInsight. Springer Nature Switzerland AG.
- 1 2 "Drospirenone/Ethinylestradiol low-dose - Bayer HealthCare Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
- 1 2 Bayer HealthCare Pharmaceuticals Inc. "Highlights of Prescribing Information: Yasmin" (PDF). U.S. Food and Drug Administration.
- 1 2 Bayer HealthCare Pharmaceuticals Inc. "Highlights of Prescribing Information: Yaz" (PDF). U.S. Food and Drug Administration. Retrieved 31 October 2017.
- ↑ Keam SJ, Wagstaff AJ (2003). "Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive". Treatments in Endocrinology. 2 (1): 49–70. doi:10.2165/00024677-200302010-00005. PMID 15871554. S2CID 209144694.
- ↑ "Ethinylestradiol/Drospirenone/Folic acid". AdisInsight. Springer Nature Switzerland AG.
- ↑ Bayer HealthCare Pharmaceuticals Inc. "Highlights of Prescribing Information: Beyaz" (PDF). U.S. Food and Drug Administration.
- ↑ "Drospirenone Uses, Side Effects & Warnings". Drugs.com.
- ↑ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
- ↑ "Drospirenone; Ethinyl Estradiol - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
External links
- "Drospirenone mixture with estradiol". Drug Information Portal. U.S. National Library of Medicine.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.